title: [De novo urologic tumors in kidney transplant patients].
abstract: BACKGROUND
  The ability of a transplant recipient to accept a graft depends on the ability of immunosuppressive drugs to regulate the immune system. Such treatments have been associated with tumor promotion and progression.
  
  
  METHODS
  A systematic literature review was carried out. Electronic searches were performed in PubMed database. The searching criterion was "urological tumors in kidney transplant recipients". The most important issues regarding incidence, urological tumor-specific features, and relevant ones about the treatment are summarized.
  
  
  RESULTS
  In renal transplant, 15% of all tumors are urological neoplasias; furthermore, they are the leading neoplastic cause of death. In transplant population the incidence rate of renal cell carcinoma (RCC), transitional cell bladder carcinoma (TCBC), testicular carcinoma (TC) and prostate cancer are increased 15, 3, 3 and 2 times respectively. Treatments used in transplant patients are similar to those employed in the general population:radical nephrectomy for the native kidney and conservative surgery for the graft are indicated for RCC. Radical prostatectomy is technically feasible for localized PC.Regarding to transitional cell carcinoma BCG or MMC is not contraindicated.
  
  
  CONCLUSIONS
  The incidence rate of cancer has increased among transplant population. These tumors can be managed following the same criteria than in general population. Because in this population the prognosis is worse for the immunosuppression, closer monitoring is required.
authors.affiliation: Unidad de Trasplante Renal, Servicio de Urología, Fundació Puigvert, Barcelona, España; Unidad de Urología Oncológica, Servicio de Urología, Fundació Puigvert, Barcelona, España. Electronic address: orodriguez@fundacio-puigvert.es.
authors.forename: O
authors.initials: O
authors.lastname: Rodríguez Faba
authors.affiliation: Unidad de Trasplante Renal, Servicio de Urología, Fundació Puigvert, Barcelona, España; Unidad de Urología Oncológica, Servicio de Urología, Fundació Puigvert, Barcelona, España.
authors.forename: A
authors.initials: A
authors.lastname: Breda
authors.affiliation: Unidad de Trasplante Renal, Servicio de Urología, Fundació Puigvert, Barcelona, España; Unidad de Urología Oncológica, Servicio de Urología, Fundació Puigvert, Barcelona, España.
authors.forename: L
authors.initials: L
authors.lastname: Gausa
authors.affiliation: Unidad de Urología Oncológica, Servicio de Urología, Fundació Puigvert, Barcelona, España.
authors.forename: J
authors.initials: J
authors.lastname: Palou
authors.affiliation: Unidad de Urología Oncológica, Servicio de Urología, Fundació Puigvert, Barcelona, España.
authors.forename: H
authors.initials: H
authors.lastname: Villavicencio
mesh_terms: D000328:Adult; D000368:Aged; D002292:Carcinoma, Renal Cell / Q000453:epidemiology / Q000209:etiology / Q000601:surgery; D002295:Carcinoma, Transitional Cell / Q000453:epidemiology / Q000209:etiology / Q000628:therapy; D005260:Female; D006801:Humans; D016867:Immunocompromised Host; D007166:Immunosuppressive Agents / Q000009:adverse effects; D015994:Incidence; D007680:Kidney Neoplasms / Q000453:epidemiology / Q000209:etiology / Q000601:surgery; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D010412:Penile Neoplasms / Q000453:epidemiology / Q000209:etiology; D011183:Postoperative Complications / Q000453:epidemiology*; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000453:epidemiology / Q000209:etiology / Q000601:surgery; D013736:Testicular Neoplasms / Q000453:epidemiology / Q000209:etiology; D001749:Urinary Bladder Neoplasms / Q000453:epidemiology / Q000209:etiology / Q000628:therapy; D014571:Urologic Neoplasms / Q000453:epidemiology* / Q000209:etiology
chemical_list: D007166:Immunosuppressive Agents
keywords: Bladder cancer; Cáncer de prostata; Cáncer renal; Cáncer vesical; Kidney transplantation; Prostate cancer; Renal cancer; Trasplante renal; Tumor urológico; Urologic tumor